- Home
- TERN vs ALMS Comparison
TERN vs ALMS Comparison
Compare TERN & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- ALMS
- Stock Information
- Founded
- TERN 2017
- ALMS 2021
- Country
- TERN United States
- ALMS United States
- Employees
- TERN N/A
- ALMS N/A
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- ALMS
- Sector
- TERN Health Care
- ALMS
- Exchange
- TERN Nasdaq
- ALMS NYSE
- Market Cap
- TERN 586.0M
- ALMS 652.3M
- IPO Year
- TERN 2021
- ALMS 2024
- Fundamental
- Price
- TERN $6.17
- ALMS $8.85
- Analyst Decision
- TERN Buy
- ALMS Strong Buy
- Analyst Count
- TERN 6
- ALMS 6
- Target Price
- TERN $16.42
- ALMS $29.60
- AVG Volume (30 Days)
- TERN 1.3M
- ALMS 78.8K
- Earning Date
- TERN 11-12-2024
- ALMS 11-13-2024
- Dividend Yield
- TERN N/A
- ALMS N/A
- EPS Growth
- TERN N/A
- ALMS N/A
- EPS
- TERN N/A
- ALMS N/A
- Revenue
- TERN N/A
- ALMS N/A
- Revenue This Year
- TERN N/A
- ALMS N/A
- Revenue Next Year
- TERN N/A
- ALMS N/A
- P/E Ratio
- TERN N/A
- ALMS N/A
- Revenue Growth
- TERN N/A
- ALMS N/A
- 52 Week Low
- TERN $3.59
- ALMS $8.23
- 52 Week High
- TERN $11.40
- ALMS $13.53
- Technical
- Relative Strength Index (RSI)
- TERN 31.82
- ALMS N/A
- Support Level
- TERN $6.99
- ALMS N/A
- Resistance Level
- TERN $7.53
- ALMS N/A
- Average True Range (ATR)
- TERN 0.47
- ALMS 0.00
- MACD
- TERN -0.02
- ALMS 0.00
- Stochastic Oscillator
- TERN 16.57
- ALMS 0.00
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.